Recent Finacing
Recent Raise
Gamida Cell develops nicotinamide‑modified allogeneic and expanded cord‑blood cell therapies— including FDA‑approved Omisirge and NiCord—targeting hematologic malignancies, genetic hematological disorders, and clinical manufacturing.
